• 1
    Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 2004;5:657667.
  • 2
    Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich). 2004;6:445451.
  • 3
    Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens. 2005;19:173183.
  • 4
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE): a randomized trial against atenolol. Lancet. 2002;359:9951003.
  • 5
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:20222031.
  • 6
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study (ELITE II). Lancet. 2000;355:15821587.
  • 7
    Cohn JN, Tognoni G. Valsartan Heart Failure trial.(ValHeFT) investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:16671675.
  • 8
    Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure. Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970975.
  • 9
    Dickstein K, Kjekshaus ., for the OPTIMAAL Steering Committee of the OPTIMAAL study. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752760.
  • 10
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767771.
  • 11
    Granger CB, McMurray JJ, Yusuf S, et al., For the CHARM Investigators and Committee. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772776.
  • 12
    Pfeffer MA, McMurray JJ, Velasquez EJ, et al., For the Valsartan Acute Myocardial Infarction Trial (VALIANT) investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203]. N Engl J Med.2003;349:1893–1906.
  • 13
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 14
    Brenner BM, Cooper ME, Dezeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 15
    Parving HH, Lehert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes (IRMA-2). N Engl J Med. 2001;345:870878.
  • 16
    Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [published correction appears in N Engl J Med. 2005;352:1731]. N Engl J Med.2004;351:1952–1961.
  • 17
    Nakao N, Ashio Y, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease. (COOPERATE): a randomized controlled trial. Lancet. 2003;361:117124.
  • 18
    Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45:880886.
  • 19
    Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. J Cardiovasc Pharmacol. 1999;33(suppl 1):S16S20.
  • 20
    Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA. 2002;288:14911498.
  • 21
    Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875886.
  • 22
    Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly. (SCOPE). J Am Coll Cardiol. 2004;44:11751180.
  • 23
    Schrader J, Lüders S, Kulschewski A, et al., For the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:12181226.
  • 24
    Takai S, Jin D, Sakaguchi M, et al. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation. 1999;100:654658.
  • 25
    Ihara M, Urata H, Kinoshita A, et al. Increased chymasedependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:13991405.
  • 26
    Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387392.
  • 27
    Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J. 1998;135:S21S30.
  • 28
    Malmqvist K, Ohman KP, Lind L, et al. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Cardiovasc Pharmacol. 2003;42:719726.
  • 29
    Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens. 2002;20:22932300.
  • 30
    Chrysant SG. Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc). 2004;40:791801.
  • 31
    Fernandez LA, Caride VJ, Stromberg C, et al. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994;24:937940.
  • 32
    Dalmay F, Mazouz H, Allard J, et al. Non-AT1-receptormediated protective effect of angiotensin against acute ischemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst. 2001;2:103106.
  • 33
    Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843848.
  • 34
    De Paolis P, Porcellini A, Gigante B, et al. Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. J Hypertens. 1999;17:18731877.
  • 35
    Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329:12481249.
  • 36
    Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005;18:134S141S.
  • 37
    McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331:873878.
  • 38
    Morawietz H, Rueckscloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation. 1999;100:899902.
  • 39
    Miyazaki M, Takai S. Antiatherosclerotic efficacy of olmesartan. J Hum Hypertens. 2002;16(suppl 2):S7S12.
  • 40
    Carey RM. Cardiovascular and renal regulation by angiotensin type 2 receptor. The AT1 receptor comes of age. Hypertension. 2005;45:840844.
  • 41
    Watanabe T, Baker TA, Berk BC. Angiotensin II and the endothelium. Diverse signals and effects. Hypertension. 2005;45:163169.
  • 42
    De Cavanagh EM, Fraga CG, Ferder L, et al. Enalapril and captopril enhance antioxidant defenses in tissues. Am J Physiol. 1997;272(pt 2):R514R518.
  • 43
    Inukai T, Yoshida N, Wakabayashi S, et al. Angiotensin-converting enzyme inhibitors and antiotensin II receptor blockers effectively and directly potentiate superoxide scavaging by polymorphonuclear-leukocytes from patients with type 2 diabetes mellitus. Am J Med Sci. 2005;329:222227.
  • 44
    Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2001;103:163182.
  • 45
    Grundy SM, Benjamin JJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:11341146.
  • 46
    Kurtz TW, Pravenec M. Antidiabetic mechanisms and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004;22:22532261.
  • 47
    Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome-activated receptorgamma activity. Circulation. 2004;109:20542057.
  • 48
    Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma modulating activity. Hypertension. 2004;43:9931002.
  • 49
    Guerra Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens. 1999;17:447452.
  • 50
    Jimenez AM, Monton M, Garcia R, et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison to losartan, candesartan and valsartan. J Cardiovasc Pharmacol. 2001;37:406412.
  • 51
    Ogata J, Fujishima M, Tamaki K, et al. Vascular changes underlying cerebral lesions in stroke-prone spontaneously hypertensive rats. A serial section study. Acta Neuropathol. (Berl). 1981;54:183188.
  • 52
    Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:11831190.
  • 53
    Fang J, Alderman MH. Serum uric acid and cardiovascular mortality, the NHANES I epidemiologic follow-up study,. 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:24042410.
  • 54
    Lehto S, Niskanen L, Ronnemaa T, et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin dependent diabetes mellitus. Stroke. 1998;29:635639.
  • 55
    Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with hypertension. Hypertension. 2000;35:746751.
  • 56
    Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Circulation. 2002;105:26192624.
  • 57
    Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:10411049.
  • 58
    Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation. 2002;106:331336.
  • 59
    Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol. 2005;45:712719.
  • 60
    Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:21972204.